Quantum Media Group, LLC’s Post

Here's an interesting article that discusses #expectations for biotech #clinicaltrials in 2024, highlighting a cautious optimism following a significant #reset in #pharma and #biotech research investment post-pandemic. Key trends include: ✓Continued #Investment Challenges: Although there's hope for renewed investment, the risk-averse nature of investors suggests that the high levels of funding seen during the pandemic are unlikely to return. ✓Focus Areas in Biotech: Specific areas like #obesity and #neurology are attracting investment, evidenced by Roche's buyout of Carmot Therapeutics and progress in Alzheimer’s drugs. ✓Challenges for Public Biotechs: Capital markets will remain difficult for public biotech companies, though there's potential for raising capital based on strong data and significant catalysts. ✓#GeneEditing and #RareDiseases: Progress in gene editing, particularly with the UK’s approval of the first CRISPR treatment for certain diseases, is expected to accelerate. Rare diseases continue to attract research attention. ✓Cancer Research Investments: #Oncology remains a major area for research investment, with an emphasis on overcoming drug resistance and the potential role of cancer vaccines. ✓Clinical Trial #Recruitment Challenges: The geopolitical landscape poses challenges for patient recruitment in clinical trials, emphasizing the need for diverse patient inclusion. ✓Rise of #AI in Clinical Research: #ArtificialIntelligence is expected to play a significant role in clinical research, particularly in interpreting health data and developing patient-centric health management tools. Overall, there is a mixed outlook for 2024 in the biotech and pharma sectors, with advancements in certain areas balanced by ongoing challenges in investment and trial recruitment.

FluoSphera is a patent-protected technology platform developing a unique set of disruptive technologies mimicking the clinical response to drugs under systemic conditions to accurately predict drug safety and efficacy. Such high-throughput systemic assays reliably identify the most promising lead compounds early during drug discovery to decrease drug development failure in the clinic, thus increasing the chance for the patients to get access to the best therapeutics while reducing animal experimentation. Meet FluoSphera @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW

The life sciences industry is witnessing a significant shift in 2024, marked by strategic advancements and a cautiously optimistic outlook. Key movements, like Roche's notable acquisition of Carmot Therapeutics, Inc., signal a focused approach towards areas with high potential, such as obesity and neurology. This trend represents a departure from the broader investment strategies of the past and underscores a more targeted direction in research and development. In this evolving landscape, the importance of aligning specialized talent with emerging fields is more pronounced than ever. Areas like gene editing and neurotechnology are not just future promises; they are rapidly growing sectors that demand a specific skill set. Despite the challenges in funding, particularly for public biotech firms, opportunities for strategic growth and innovation remain. For our company, resilience and adaptability are key virtues as we navigate these changes. Our focus is on staying agile and responsive to the industry’s needs, ensuring that we are well-positioned to support and drive progress in this dynamic phase. https://lnkd.in/ee4PUY92 #lifesciences #AspireLifeSciences #biotech #clinicaltrials #2024trends #2024

Allow us to share with you the joy of our recent investment in Lime Therapeutics 🔬 – US-based biotech startup developing a game-changing drug discovery platform. Using an ultrasensitive lipid detection technology, the platform is able to target conditions such as cancer, metabolic disorders, and neurodegenerative diseases. Founded by a team with expertise in immunology, nanosensor technologies, and drug discovery, Lime Therapeutics has established relevant partnerships with pharmaceutical companies. 🤝 Huge congrats to the core team | Shardule Shah, PhD, MBA | Prakrit Jena | Daniel Heller | Mariluz Soula, PhD | on their progress up to date and looking forward to watching their future path 🚀 For more info see the link to a full article in comments. #investment #startup #biotech #lipidmetabolism #lipidbiology #lipiddysfunction #cancersucks #stopcancer #drugdiscovery

💡Biotech's most innovative in 2024 were announced by Fast Company this week and as ever there is a great blend of technology. Here's the Top 10 below 👇 1️⃣ Insilico Medicine - focusing on drug-disease targets. 2️⃣ ElevateBio - Catching genetic disorders at the root. 3️⃣ Personalis, Inc. - Deetecting cancers early. 4️⃣ Exscientia - AI to personalize cancer treatments. 5️⃣ Rocket Pharmaceuticals - Targeting rare diseases with gene therapy. 6️⃣ Guardant Health - Cancer detection and drug development. 7️⃣ Inato - Bringing clinical trials to local hospitals. 8️⃣ Elucidata - Cleaning up messy biomedical data. 9️⃣ Maravai LifeSciences - Improving the safety of immunotherapy. 🔟 Emerald Cloud Lab - Providing 24/7 lab services in the cloud. 🧑🔬 Its great to see companies receive recognition for hard work especially given the different stages they are on. Nice to see Personalis and Guardant represent the #LiquidBiopsy market too 🩸! #fcmostinnovative #biotech

NAYA buys Florida Biotechnologies for $20M to get hold of rare genetic disease drug: Fellow Floridians NAYA Biosciences is set to acquire developer Florida Biotechnologies for $20 million in shares as part of the portfolio-focused company’s search for disruptive clinical-stage therapies. For this Florida Biotech, it was their therapy for a rare genetic disease called Leber’s hereditary optic neuropathy (LHON). The biotech has already put a first-generation candidate through a phase 1 trial, demonstrating curative results without any adverse effects. NAYA has entered a binding term sheet with Florida Biotech that means NAYA acquires all the biotech’s outstanding stock in exchange for $20 million worth of NAYA’s shares. Florida Biotech’s shareholders would also be in line for $5 million in milestone payments down the line. Read more to see what Florida Biotech’s cofounder Peter Kash said about the NAYA leadership team brings to the company: #naya #biotech #genetherapy

🔬 We're thrilled to offer a glimpse into the Tumor Microenvironment Track at our upcoming Immuno-Oncology Xchange event in Boston! 🎉 📌Secure your spot and register for free: https://bit.ly/4clU9OU Don't miss this opportunity to explore more into tumor microenvironment in immuno-oncology! Connect with industry experts and gain valuable insights! ⭐ Here's the highlights: 📑 Learning from patient-derived autoantibodies to understand human tumor biology and identify new targets. 🗣️ Xingfeng Bao, VP Head of Biology, GV20 Therapeutics 📑 How to overcome suppressive Tumor Microenvironment, Mechanism, Hurdles, and Innovative Therapeutic Modalities. 🗣️ Dharini Shah, Senior Director (Cell Therapy, Oncology), Sanofi 💊 Only available for Senior Scientists and above, from Bio and Pharma companies with a drug pipeline. 💊 🤝 Our Partners ‣ Biorasi ‣ Enable Medicine ‣ Oncocyte Corporation ‣ Flagship Biosciences, Inc. ‣ WuXi Advanced Therapies ‣ CDI Labs ‣ Nona Biosciences * Agenda subject to change. #ImmunoOncology #CancerResearch #Biotech #Pharma #TumorMicroenvironment #BostonEvents #PharmaEvent #NetworkingEvent #IOtherapy #CancerTherapies #OncologyResearch #BostonNetworking #OncologyInnovation #CancerTreatment #PrecisionMedicine #DrugDevelopment #Biopharma #Bioinformatics #MedicalResearch #Healthcare #BostonLifeScience #InnovationInHealth #ClinicalTrials #BiomarkerDiscovery #ScienceNetworking #ResearchCollaboration #BiomedicalScience #PrecisionOncology #HealthInnovation #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimenatryPass

Phialogics is a preclinical biotech company specialized in engineering next-generation biologics to rebalance the immune response in acute and chronic inflammation. Phialogics concept is based on the targeted modification of immunoglobulin receptor domains (IgVs) to modulate immune response in inflammatory diseases. IgV mediated receptor-ligand interaction represents a significant source of novel biologics. Phialogics lead molecules replicate endogenous protein-protein interactions to efficiently modulate the function of their target receptor. So far, only this unique platform technology can achieve such a high level of precision. Meet Phialogics AG @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW

[Portfolio news] Insightful article from Labiotech.eu featuring 19 promising French biotech companies, with two shining stars from our portfolio! 🌐💼 🌟 DiogenX focuses on regenerating insulin-producing beta cells to transform diabetes treatment while SparingVision develops a pipeline of gene therapies for inherited retinal diseases. Their recent milestones, from funding successes to clinical advancements, underscore the strength of our investment strategy. Quietly leading in the biotech landscape, our portfolio companies reflect the remarkable potential found in #France. Our #early investment strategy in France, dating back to 2017, has positioned us at the forefront of biotech innovation. DiogenX and SparingVision exemplify the prowess of the French biotech landscape, where groundbreaking ideas flourish into globally recognized ventures. 🚀 Investing early, fostering excellence – that's our commitment to shaping the future of healthcare. #Biotech #VentureBuilder #French #Innovation #DiogenX #SparingVision Benjamin CHARLES Stephane Boissel Alain Huriez Geoffroy De Ribains

I love "pat-on-the-back" moments... especially when Chris De Savi (a highly insightful scientist) from Curie.Bio shows a deep understanding (maybe a deep interest?) of new modalities I started to look into about 12-15 months ago: PROteolysis TArgeting Chimeras (#PROTACs) and Molecular Glue Degraders (#MGDs) These new modalities are quite fascinating as they will likely expand the targeting space of existing and new drugs. As Monte Rosa Therapeutics, a leader in MGD development, rightly puts it: ➡ PROTACs could allow to "redrug the druggable", while ➡ MGDs could allow to "drug the undruggable" Very recently, Sudhir Nambiar posted a useful post (https://lnkd.in/eKK8TKEv) with a list of selected PROTACs and MGDs programs in clinical trials. 🙏 The trained eye will have noticed that most clinical trials are in oncology, most often in 3rd or 4th line indications. The reason for that seems quite simple: toxicity side effects linked to protein degradation has been limiting its applications so far. As such, they have mostly been developed extremely late-stage diseases, where toxicity is unfortunately less of an issue... For that reason, I am quite excited to follow the work of companies such as Kymera Therapeutics (focusing on PROTACs) and Monte Rosa Therapeutics (focusing on MGDs) as their pipelines extend beyond oncology... and into auto-immune, inflammatory and neurology diseases. Big Pharmas and Big Biotechs are increasingly investigating the potential of such new modalities, either internally or through collaborations. 🔬💲 As an example, Roche recently announced a strategic collaboration with Monte Rosa Therapeutics to discover novel MGDs with an upfront payment of $50 million and potential future payments exceeding $2 billion. #biotech #lifesciences #mergersandacquisitions